Haematology Blood Markers

Oxygen-carrying protein in red blood cells.

PED: AAS stimulate erythropoiesis (red blood cell production), increasing haemoglobin. This is a significant cardiovascular risk as high haemoglobin increases blood viscosity, raising stroke and heart attack risk. Values >180 g/L are concerning and warrant immediate intervention. EQ (Boldenone) is particularly notorious for raising haemoglobin.

Percentage of blood volume occupied by red blood cells.

PED: Directly related to haemoglobin. AAS increase haematocrit. Values >0.52 increase stroke and cardiovascular risk significantly. EQ (Boldenone) is particularly notorious for raising haematocrit.

Number of red blood cells per liter of blood.

PED: Increased by AAS-stimulated erythropoiesis. Follows haemoglobin and haematocrit trends.

Number of white blood cells. Important for immune function.

PED: Not typically significantly affected by AAS. Intense training can temporarily elevate. Low values may indicate overtraining or immune suppression.

Cell fragments essential for blood clotting.

PED: Generally not significantly affected by AAS. Monitor if using compounds that affect clotting or if taking aspirin/NSAIDs regularly.

Average size of red blood cells. Helps classify types of anemia.

PED: Not typically affected by AAS. Low MCV with low iron suggests iron deficiency from blood donations.

Average amount of haemoglobin per red blood cell.

PED: Not typically affected by AAS. Low MCH with low MCV suggests iron deficiency, common in athletes who donate blood regularly to manage high haematocrit.

Average concentration of haemoglobin in red blood cells.

PED: Not typically affected by AAS. Low MCHC can indicate iron deficiency. Useful alongside MCH and MCV to classify anaemia type.

Measures variation in red blood cell size. Elevated in mixed deficiency states.

PED: Can be elevated when iron is depleted from regular blood donations while AAS are stimulating new red blood cell production. A high RDW with normal MCV may indicate early iron deficiency.

Most abundant white blood cell type. First responders to bacterial infection.

PED: Can be transiently elevated after intense training. Chronic elevation may indicate infection or inflammation. Not typically directly affected by AAS.

White blood cells important for adaptive immunity (B cells, T cells, NK cells).

PED: Can be suppressed by overtraining or extreme caloric restriction during contest prep. Chronic low lymphocytes may indicate immune suppression.

White blood cells that differentiate into macrophages. Part of innate immunity.

PED: Not typically significantly affected by AAS. May be elevated with chronic inflammation or infection.

White blood cells involved in allergic responses and parasitic infections.

PED: Not typically affected by AAS. Elevation may indicate allergic reaction, parasitic infection, or certain medications.

Rarest white blood cell type. Involved in allergic and inflammatory responses.

PED: Not typically affected by AAS. Usually present in very small numbers. Rarely clinically significant in isolation.

Average size of platelets. Larger platelets are younger and more reactive. Can indicate bone marrow activity.

PED: Not directly affected by AAS. May increase when platelet turnover is high (e.g. from heavy training-induced microtrauma). Persistently elevated MPV with low platelets warrants investigation.

Immature red blood cells released from bone marrow. The absolute count is the most reliable indicator of bone marrow erythropoietic activity.

PED: AAS stimulate erythropoiesis via increased EPO production, suppressed hepcidin, and direct bone marrow stimulation — reticulocyte counts are typically elevated on cycle. Boldenone (EQ) has particularly marked erythropoietic effects. After blood donation (common for managing high haematocrit), reticulocytes spike within 3-6 days and normalise by 9-12 days. EPO use produces dramatic elevations — counts doubling from baseline is characteristic.

Percentage of immature granulocytes (metamyelocytes, myelocytes, promyelocytes) in peripheral blood. Normally near zero; elevation indicates bone marrow stimulation or infection.

PED: AAS stimulate granulopoiesis — stanozolol has been shown to accelerate neutrophil precursor maturation in bone marrow. EPO use stimulates broad haematopoiesis including granulocyte production. Intense training itself can cause transient elevation via exercise-induced bone marrow stimulation. Mild elevation (0.5-2%) is common in enhanced athletes and usually benign. Values >3% warrant investigation for infection or bone marrow pathology regardless of PED use.

Red blood cell precursors normally confined to bone marrow. Their presence in peripheral blood indicates severe erythropoietic stress, bone marrow pathology, or extramedullary haematopoiesis.

PED: EPO use and AAS-driven erythropoiesis can push NRBCs into peripheral blood, especially at high doses. High-dose testosterone, trenbolone, and equipoise (boldenone) are strongly erythropoietic. NRBCs are rare even in enhanced athletes — their presence at >1/100 WBC is always clinically significant and warrants investigation. Combined AAS + EPO use increases risk. Severe polycythaemia (HCT >54%) can be accompanied by NRBCs.

Absolute count of nucleated red blood cells per microlitre of blood. Reported on modern automated haematology analysers alongside the relative count (per 100 WBCs). Any value above 0 indicates erythropoietic stress, bone marrow pathology, or extramedullary haematopoiesis.

PED: Same clinical entity as NRBC per 100 WBCs but expressed as an absolute concentration. The Sysmex XN, Beckman DxH, and Abbott Alinity haematology platforms now report this alongside the relative NRBC count. In enhanced athletes, the most common driver is aggressive erythropoietic stimulation: high-dose testosterone, trenbolone, equipoise, and exogenous EPO can push nucleated RBCs into peripheral circulation. Combined AAS plus EPO use is the highest-risk pattern. Severe polycythaemia (HCT above 54%) increases the likelihood of detectable absolute NRBC. Any value above 0.01 K/uL warrants attention and a full erythropoietic panel (haemoglobin, haematocrit, reticulocyte count). Persistent elevation without obvious PED cause requires haematology referral and bone marrow evaluation.

The proportion of white blood cells that are neutrophils, expressed as a percentage of the total. This is the relative differential value, distinct from the absolute neutrophil count. Because it is a proportion, it shifts whenever any other white-cell line rises or falls, so it is best interpreted alongside the absolute count.

PED: A relative value, so read it together with the absolute neutrophil count and the rest of the differential. Intense training transiently raises the neutrophil percentage (a demargination/stress response), which normalises within a day; always use a rested draw. It is not directly altered by AAS, though the neutrophil-to-lymphocyte relationship is sometimes used as a rough systemic-inflammation gauge in athletes.

The absolute neutrophil count divided by the absolute lymphocyte count. It is a simple, inexpensive index of systemic inflammation and physiological stress derived from a standard full blood count. A higher ratio reflects a shift toward innate (neutrophil) immunity and away from lymphocytes, a pattern seen with inflammation, infection, and stress.

PED: A useful low-cost gauge of systemic inflammation and training stress in athletes, best read as a trend rather than a single value. Hard training, overtraining, and acute physical or psychological stress raise the ratio through a cortisol-driven neutrophilia plus lymphopenia; it typically normalises within a day of rest, so use a rested, non-post-workout draw. It is not directly altered by AAS, but a persistently elevated NLR in an enhanced athlete can flag chronic inflammation or under-recovery worth investigating alongside CRP. Values are only meaningful when both the neutrophil and lymphocyte counts are themselves valid, so always interpret it with the full differential.

The proportion of white blood cells that are lymphocytes, expressed as a percentage of the total. This relative differential value is distinct from the absolute lymphocyte count and shifts with changes in any other white-cell line, so it should be interpreted alongside the absolute count.

PED: A relative value best read with the absolute lymphocyte count. In athletes, a low lymphocyte percentage can accompany the acute post-exercise state or, if persistent alongside a low absolute count, may signal overtraining, severe contest-prep caloric deficit, or chronic stress. A high percentage is most often a relative rise during viral infection. Not directly changed by AAS.

The proportion of white blood cells that are monocytes, expressed as a percentage of the total. This relative differential value is distinct from the absolute monocyte count and is best interpreted alongside it, since it shifts with changes in other white-cell lines.

PED: A relative value, rarely actionable in isolation. Mild elevation of the monocyte percentage can accompany recovery from infection or chronic low-grade inflammation, which in athletes may reflect ongoing musculoskeletal inflammation or overuse. Not directly affected by AAS. Interpret alongside the absolute count and inflammatory markers such as CRP.

The proportion of white blood cells that are eosinophils, expressed as a percentage of the total. This relative differential value is distinct from the absolute eosinophil count and should be interpreted alongside it.

PED: A relative value most useful when read with the absolute eosinophil count. Elevated eosinophil percentage most often reflects allergy or atopy, and sometimes parasitic infection or a drug/supplement reaction. Not directly affected by AAS, though new supplements and injectable excipients can occasionally trigger a reaction. Interpret alongside the absolute count and clinical history.

The proportion of white blood cells that are basophils, expressed as a percentage of the total. Basophils are the rarest white-cell type, so this value is normally very low. It is the relative differential value, distinct from the absolute basophil count.

PED: The rarest white-cell line and rarely significant in isolation. A mildly raised basophil percentage is almost never meaningful on its own; persistent elevation can occasionally accompany allergic conditions, hypothyroidism, or, rarely, myeloproliferative disorders. Not affected by AAS. Interpret within the full differential.

A measure of the variability in platelet size (the width of the platelet size distribution). A higher PDW means platelets vary more in size, which reflects differences in platelet production and turnover. It is reported automatically as part of the platelet indices on a full blood count.

PED: A minor platelet index, most useful read alongside platelet count and mean platelet volume (MPV) rather than alone. A raised PDW indicates a more heterogeneous, often more active platelet population and tends to move with MPV. It is not directly affected by AAS, but because enhanced athletes carry elevated cardiovascular risk (erythrocytosis, blood pressure, lipid shifts), platelet indices are occasionally noted as part of the broader thrombotic-risk picture. On its own it is rarely actionable.

The fraction of blood volume occupied by platelets, analogous to the haematocrit for red cells. It is calculated from the platelet count and mean platelet volume and reflects total platelet mass. It is reported as one of the platelet indices on a full blood count.

PED: A minor platelet index that summarises total platelet mass, best interpreted with the platelet count and MPV. Note the common source-PDF mislabel: some labs print plateletcrit under a 'PCT' abbreviation, and it can be confused with platelet distribution width, but the percentage unit identifies it as plateletcrit. Not directly affected by AAS; occasionally relevant to the broader thrombotic-risk picture in enhanced athletes with erythrocytosis or hypertension, but rarely actionable in isolation.

Measures the time for blood to clot via the intrinsic and common coagulation pathways. Used to screen for clotting factor deficiencies and to monitor unfractionated heparin therapy.

PED: APTT itself is not a routine PED monitoring test, but coagulation matters for enhanced athletes. Androgens (testosterone and other AAS) drive erythropoiesis, and the resulting rise in haematocrit thickens the blood and raises thrombotic risk independent of any clotting-time change. AAS also shift the haemostatic balance toward a prothrombotic state (altered fibrinolysis, platelet activation, and changes in clotting factor and antithrombin levels), so a normal APTT does NOT mean clot risk is low if haematocrit is high. APTT is the standard test used to monitor unfractionated heparin if anticoagulation is ever required. No PED shifts the healthy target range, so the bodybuilder reference range equals the standard range.

Measures the time for blood to clot via the extrinsic and common coagulation pathways. Sensitive to clotting factors I, II, V, VII and X, and used to assess liver synthetic function and vitamin K status.

PED: PT is not a routine PED test, but it is a useful window on liver synthetic function, which matters for users of oral 17-alpha-alkylated AAS. The liver makes most clotting factors, so significant AAS-induced hepatotoxicity can prolong PT. Separately, androgen-driven erythrocytosis raises thrombotic risk through elevated haematocrit rather than through PT, so a normal PT does not exclude clot risk in a polycythaemic athlete. PT (as the INR) is the standard test to monitor warfarin. No PED shifts the healthy target, so the bodybuilder range equals the standard range.

A standardised expression of the prothrombin time that corrects for differences between laboratory reagents. Used mainly to monitor warfarin (vitamin K antagonist) therapy and to assess liver synthetic function.

PED: INR is not a PED marker, but it is the standard way to report prothrombin time and to gauge liver synthetic capacity, which is relevant for oral 17-alpha-alkylated AAS users. A rising INR off anticoagulation can signal impaired hepatic clotting factor synthesis. Note the direction of risk: androgen use raises clotting risk (through elevated haematocrit and a prothrombotic shift), whereas a HIGH INR reflects slower clotting and bleeding risk, so the two are not opposites of the same axis. No PED shifts the healthy target; the bodybuilder range equals the standard range.

Measures the time for fibrinogen to convert to fibrin after thrombin is added, isolating the final step of clot formation. Sensitive to fibrinogen level and function and to thrombin inhibitors such as heparin and direct thrombin inhibitors.

PED: Thrombin clotting time (also called thrombin time) is a specialised coagulation test, not a routine PED marker. It is prolonged by low or dysfunctional fibrinogen and by anticoagulants that inhibit thrombin (heparin, dabigatran). For enhanced athletes, the more important coagulation issue is androgen-driven erythrocytosis raising haematocrit and clot risk, which the TCT does not measure. No PED shifts the healthy target, so the bodybuilder range equals the standard range.

A fibrin degradation product released when a blood clot is broken down. Used to help rule out venous thromboembolism (deep vein thrombosis and pulmonary embolism) and to assess disseminated intravascular coagulation.

PED: D-dimer is highly relevant to enhanced athletes because AAS increase thrombotic risk: androgen-driven erythrocytosis raises haematocrit and blood viscosity, and AAS shift haemostasis toward clotting and impaired fibrinolysis. A raised D-dimer signals active clot formation and breakdown somewhere in the body, so in a polycythaemic user with leg swelling, chest pain, or breathlessness it is an urgent finding. D-dimer is most useful for its negative predictive value: a normal result makes clinically significant clot very unlikely. It is non-specific and rises with inflammation, hard training, injury, and recent surgery. No PED lowers the healthy target, so the bodybuilder range equals the standard range.

A clotting protein made by the liver that thrombin converts to fibrin, the structural mesh of a blood clot. It is also an acute-phase reactant and an independent cardiovascular risk marker.

PED: Fibrinogen matters for enhanced athletes on two fronts. First, it is a clotting factor, so higher levels contribute to a more prothrombotic state, compounding the clot risk from androgen-driven erythrocytosis and high haematocrit. Second, it is an acute-phase protein that rises with inflammation, so heavy training, high body fat, and the low-grade inflammation seen on some cycles can push it up. A persistently high fibrinogen is an independent cardiovascular risk factor, which is directly relevant to the cardiovascular focus of harm reduction in PED users. No PED shifts the healthy target, so the bodybuilder range equals the standard range.